Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study from Department of Physiology, Anatomy & Genetics has addressed a long-standing gap in our understanding of systemic iron homeostasis. It provides the first formal demonstration that the hormone hepcidin controls iron reabsorption in the kidney, in a manner that impacts the body’s iron levels, under normal physiological conditions. It also demonstrates for the first time how this mechanism becomes critically important in the development of iron disorders.

Illustration showing iron reabsorption
In addition to absorption in the gut and recycling in the spleen, iron is also obtained through reabsorption in the kidney

Iron levels in the body are largely controlled by activity in two key organs: the gut, where we absorb iron from our diet, and the spleen, where we recycle red blood cells. The hormone hepcidin controls the availability of iron in the blood stream by inhibiting the iron exporter ferroportin in the gut and spleen. It has long been speculated that a third organ could be involved: an abundance of ferroportin has been observed in the kidney, implicating it in the reabsorption of iron from urine back into the circulation. However, the extent to which the kidney contributes to the regulation of iron in the body has so far been little understood. We do not know how important the kidney iron reabsorption is, nor how it is regulated.

A new study from the Lakhal-Littleton Research Group (Department of Physiology, Anatomy & Genetics - DPAG) has formally demonstrated that the kidney indeed reabsorbs iron back into the blood stream using ferroportin. Their findings show that if ferroportin in the kidney is blocked, there is a reduction in the body’s iron levels, which is quickly corrected by a compensatory increase in gut iron absorption.  According to Associate Professor Samira Lakhal-Littleton: “This means that under normal physiological conditions, the kidney is a less important  source of iron than the gut and spleen.”

Read the full story on the DPAG website.

Similar stories

Language learning difficulties in children linked to brain differences

A new study using MRI has revealed structural brain changes in children with developmental language disorder (DLD), a common but under-recognised difficulty in language learning. Children with DLD aged 10-15 showed reduced levels of myelin in areas of the brain associated with speaking and listening to others, and areas involved in learning new skills. This finding is a significant advance in our understanding of DLD and these brain differences may explain the poorer language outcomes in this group.

The Gene Therapists Headline at Glastonbury 2022

Rosie Munday writes about her experience taking science to the masses at the Glastonbury Festival.

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.

Night-time blood pressure assessment is found to be important in diagnosing hypertension

Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.

Major new NIHR Global Health Research Unit to focus on data science and genomic surveillance of antimicrobial resistance

The Centre for Genomic Pathogen Surveillance, part of the Big Data Institute at the University of Oxford, has been awarded funding worth £7m for their work as an NIHR Global Health Research Unit (GHRU) for the next five years. The Centre’s research and capacity building work focuses on delivering genomics and enabling data for the surveillance of antimicrobial resistance (AMR).